Corbus Pharmaceuticals Holdings, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Corbus Pharmaceuticals Holdings, Inc. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $9.07M.
- Corbus Pharmaceuticals Holdings, Inc. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $2.88M, a 91.96% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. stock issued during period, value, new issues for the quarter ending 2024-12-31 was $0.00.
- Corbus Pharmaceuticals Holdings, Inc. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $35.84M, a 511928.57% increase year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. stock issued during period, value, new issues for fiscal 2024 was $180.24M, a 165255.05% increase from fiscal 2023.
- Corbus Pharmaceuticals Holdings, Inc. stock issued during period, value, new issues for fiscal 2023 was $109.00K, a 10899900.00% increase from fiscal 2022.
- Corbus Pharmaceuticals Holdings, Inc. stock issued during period, value, new issues for fiscal 2022 was $1.00, a 100.00% decline from fiscal 2021.
- Corbus Pharmaceuticals Holdings, Inc. stock issued during period, value, new issues for fiscal 2021 was $59.11M, a 56.65% decline from fiscal 2020.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $9.07M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $2.88M 10-Q · filed 2025-11-12 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $180.24M 10-K · filed 2026-03-09 |
| 2024-09-30 | $35.84M 10-Q · filed 2025-11-12 | $180.24M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $35.63M 10-Q · filed 2025-08-05 | $144.40M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $108.76M 10-Q · filed 2025-05-06 | $108.87M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $109.00K 10-K · filed 2025-03-11 |
| 2023-09-30 | $7.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $103.00K 10-Q · filed 2024-08-06 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $1.00 10-K · filed 2024-03-12 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $250.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $1.00 10-Q · filed 2023-05-09 | $250.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $59.11M 10-K · filed 2023-03-07 |
| 2021-09-30 | $250.00K 10-Q · filed 2021-11-12 | $80.91M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $92.00M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $58.86M 10-Q · filed 2022-05-10 | $152.19M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $21.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $136.36M 10-K · filed 2022-03-08 |
| 2020-09-30 | $11.33M 10-Q · filed 2021-11-12 | $114.56M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $60.19M 10-Q · filed 2021-08-12 | $103.23M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $43.04M 10-Q · filed 2021-05-13 | $43.04M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $37.72M 10-K · filed 2021-03-15 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2020-11-09 | $37.72M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q 3 month · filed 2020-08-31 | $37.71M derived: sum of 4 quarters · filed 2020-08-31 |
| 2019-03-31 | $37.72M 10-Q · filed 2020-05-11 | $37.76M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $11.24M 10-K · filed 2020-03-16 |
| 2018-09-30 | -$11.51K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $46.19M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | $52.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $46.20M derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $11.19M 10-Q · filed 2019-05-09 | $46.13M derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $34.96M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $75.40M 10-K · filed 2019-03-12 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $41.87M derived: sum of 4 quarters · filed 2018-03-12 |
| 2017-06-30 | -$22.23K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $41.87M derived: sum of 4 quarters · filed 2018-03-12 |
| 2017-03-31 | $40.47M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $16.30M 10-K · filed 2018-03-12 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |